Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps
Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps
复制标题
DOI：
10.1080/1744666x.2023.2246660
复制
发表时间：
2023-08
影响因子：
4.4
通讯作者：
Xian Li;Jingyun Li;Xu-xiang Xu-Xu-xiang-Xu-90058220;Wenyu She;Chengshuo Wang;Yuan Zhang;Luo Zhang
中科院分区：
文献类型：
--
作者：
Xian Li;Jingyun Li;Xu-xiang Xu-Xu-xiang-Xu-90058220;Wenyu She;Chengshuo Wang;Yuan Zhang;Luo Zhang
慢性鼻窦炎伴鼻息肉（CRSwNP）仍然是一种常见且具有挑战性的临床疾病，其经济负担迄今在中国尚未得到很好的描述。方法对101例接受鼻内镜手术的CRSwNP患者进行术后第一年的直接费用调查。门诊就诊费用、用药费用和检查费用从医院信息系统获得，并比较亚组之间的差异。采用多元线性回归分析，探讨影响CRSwNP患者年直接总费用的主要因素。结果92名受试者完成了研究。CRSwNP患者术后1年的个人平均总直接成本为742.4美元。最大的贡献者是药房费用（580.2美元），其次是检查费用（108.1美元）和门诊费用（54.1美元）。与对照组相比，临床状态不受控制、哮喘合并症和嗜酸性CRSwNP患者亚组的总直接成本更高。主要影响因素为临床控制状况（P = 0.016）和哮喘合并症（P = 0.035）。结论CRSwNP术后1年个体平均总直接成本为742.4美元。临床控制状况和哮喘合并症影响这些成本，因此对指导CRSwNP管理的卫生资源分配具有重要意义。
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) remains a common and challenging clinical entity, and its economic burden has not been well described in China thus far. Methods A total of 101 CRSwNP patients who underwent endoscopic sinus surgery were included to investigate direct costs in the first year post-surgery. Costs for outpatient visits, medication use, and examination costs were obtained from the Hospital Information System, and differences were compared between subgroups. Multiple linear regression analysis was adopted to investigate the main influencing factors on annual total direct costs for CRSwNP patients. Results Ninety-two subjects completed the study. The individual mean total direct cost for a CRSwNP patient 1 year post-surgery was $742.4. The largest contributors were pharmacy costs ($580.2), followed by examination costs ($108.1) and outpatient visits ($54.1). Total direct costs were higher in subgroups of patients with uncontrolled clinical status, asthma comorbidity, and eosinophilic CRSwNP compared to their counterparts. The main influencing factors were clinical control status (P = 0.016) and asthma comorbidity (P = 0.035). Conclusions The individual mean total direct cost of CRSwNP in 1-year post-surgery was $742.4. Clinical control status and asthma comorbidity influence these costs and are therefore important in guiding health resources allocation for CRSwNP management.